Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Project to Develop Maternal Blood Test for Rapid Fetal Oxygen Deprivation Detection

By LabMedica International staff writers
Posted on 09 Sep 2026

Intrapartum fetal hypoxia remains difficult to assess with existing monitoring, leaving clinicians to make time-critical decisions with incomplete data. More...

Limited detection and interpretation can contribute to missed fetal distress, preventable birth injuries, and avoidable cesarean deliveries. To provide clearer physiologic insight during labor, a new project aims to noninvasively quantify molecular signals of fetal oxygenation and improve clinical decision-making.

The Wyss Institute at Harvard University has received a contract of up to USD 12 million from the Advanced Research Projects Agency for Health’s Making Obstetrics Care Smart (MOCS) program to develop the Fetal Extracellular Vesicle Monitoring of Oxygenation (FEMOx) technology. FEMOx is designed as a molecular diagnostic that quantifies small, stable RNA species known as microRNAs (miRNAs) whose expression levels change with the degree of fetal oxygen deprivation. The approach targets extracellular vesicles (EVs) present in maternal blood as an accessible window into fetal and placental physiology during labor.

The workflow integrates multiple innovations into a unified platform. A maternal whole‑blood sample is introduced into a multilayer microfluidic chip that first isolates cell‑free plasma and then enriches placental EVs using integrated high‑affinity antibody arrays. On‑chip, an ambient nucleic acid molecular sensing process employs a cell‑free sensor technology, INSPECTR, to translate hypoxia‑associated miRNAs into bioluminescent signals. The signal pattern is envisioned to be read by a portable point‑of‑care detector and analyzed via a cloud‑based machine‑learning algorithm to yield clinically relevant values for risk stratification during labor.

The project assembles cross‑disciplinary teams spanning technology development and clinical practice. Clinical collaborators from Massachusetts General Hospital and Brigham and Women’s Hospital will provide regular end‑user feedback as the team builds and prototypes a diagnostic device. The effort will align with success‑driven MOCS guidelines, engage stakeholders such as regulatory professionals, industry partners, and payers, and collaborate with other MOCS awardees to address this unmet obstetric challenge.

“Clinicians are often forced to make critical decisions with unreliable information, leading to unnecessary cesarean deliveries, missed fetal distress, and preventable birth injuries with sometimes lifelong consequences[…] Technologies developed across multiple Wyss faculty labs uniquely position the Institute to make rapid detection of fetal oxygen deprivation during labor a clinical reality,” said Peter Nguyen, Ph.D., Wyss Senior Scientist.

“In the FEMOx project, we will capitalize on several recently developed Wyss technologies that enable us to isolate and concentrate tiny so‑called extracellular vesicles (EVs) from maternal blood samples and determine hypoxia‑associated molecular signatures in them. EVs are released by virtually all cells in the body and found in biofluids such as blood, and they carry cargo, including miRNA molecules, from their cells of origin. In fact, about 10 to 15% of EVs in maternal blood are derived from fetal tissues and the placenta, which provide a window into feto‑maternal communication, including the flow of oxygen,” stated Sandy Elmehrath, Ph.D., Wyss Scientist.

Related Links
The Wyss Institute at Harvard University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.